Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy

Junko Tanuma1*, Kazumi Sano2, Katsuji Teruya1, Koji Watanabe1, Takahiro Aoki1, Haruhiro Honda1, Hirohisa Yazaki1, Kunihsa Tsukada1, Hiroyuki Gatanaga1, Yoshimi Kikuchi1, Shinichi Oka1

1 AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, 2 Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University, Tokyo, Japan

Abstract

Objective: Based on drug-drug interaction, dose reduction of rifabutin is recommended when co-administered with HIV protease inhibitors for human immunodeficiency virus (HIV)-associated mycobacterial infection. The aim of this study was to compare the pharmacokinetics of rifabutin administered at 300 mg/day alone to that at 150 mg every other day combined with lopinavir-ritonavir in Japanese patients with HIV/mycobacterium coinfection.

Methods: Plasma concentrations of rifabutin and its biologically active metabolite, 25-O-desacetyl rifabutin were measured in 16 cases with HIV-mycobacterial coinfection. Nine were treated with 300 mg/day rifabutin and 7 with 150 mg rifabutin every other day combined with lopinavir-ritonavir antiretroviral therapy (ART). Samples were collected at a median of 15 days (range, 5–63) of rifabutin use.

Results: The mean Cmax and AUC0–24 of rifabutin in patients on rifabutin 150 mg every other day were 36% and 26% lower than on 300 mg/day rifabutin, while the mean Cmax and AUC0–24 of 25-O-desacetyl rifabutin were 186% and 152% higher, respectively. The plasma concentrations of rifabutin plus its metabolite were similar between the groups within the first 24 hours, but it remained low during subsequent 24 to 48 hours under rifabutin 150 mg alternate day dosing.

Conclusion: Rifabutin dose of 150 mg every other day combined with lopinavir-ritonavir seems to be associated with lower exposure to rifabutin and its metabolite compared with rifabutin 300 mg/day alone in Japanese patients. Further studies are needed to establish the optimal rifabutin dose during ART. The results highlight the importance of monitoring rifabutin plasma concentration during ART.

Trial registration: UMIN-CTR (http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function = search&action = input&language = E) UMIN000001102

Introduction

Rifabutin is commonly used for human immunodeficiency virus (HIV)-associated mycobacterial infections, especially during combination antiretroviral therapy (cART) containing HIV protease inhibitors (PIs), since it is less likely to induce hepatic microsomal enzymes than rifampicin [1–4]. Conversely, rifabutin and its active metabolite, 25-O-desacetyl rifabutin, are substrates of CYP 3A4 and concomitant use of PIs can elevate blood concentrations of rifabutin and 25-O-desacetyl rifabutin [3–8]. Such rise can increase the risk of side effects such as anterior uveitis [2,9–12]. Thus, a lower dose of rifabutin has been recommended in patients treated with PIs.

The previously recommended dose of rifabutin in combination with ritonavir-boosted PI (PI/r) [13] of 150 mg every other day, was associated with low rifabutin plasma concentrations and increases rate of acquired rifamycin resistance [14–17]. Furthermore, the Tuberculosis Trials Consortium (TBTC)/US Public Health Service Study 23 [14] suggested that AUC0–24 of 4.5 μg/mL is the cutoff value for risk of emergence of resistance to rifamycin. On the other hand, the combination of rifabutin at 150 mg thrice weekly with atazanavir-ritonavir provides exposure to rifabutin comparable to that of rifabutin 300 mg alone [11]. Thus, although 150 mg/day is the current recommended dose for rifabutin during PI/r-based cART [4], the optimal dose of rifabutin when used with a PI/r regimen remains to be established.

Ethnic differences, including body weight, renal clearance and various genetic factors like single nucleotide polymorphism (SNP), haplotype or DNA methylation [18,19], may alter the dose required to achieve a particular concentration of the drug in the circulation. Thus, pharmacokinetic studies involving different ethnic groups are needed to determine the recommended dose that take such factors into account. To our knowledge, there are no such pharmacokinetic studies for rifabutin use in Asians, who
are characterized by lower body weight compared with other ethnic groups. The present study was conducted to evaluate the pharmacokinetics of rifabutin in Japanese patients with HIV-1-related mycobacterial infection when used alone at 300 mg/day without cART and at 150 mg every other day when used in combination with lopinavir/ritonavir.

Methods
Ethics Statement
The study protocol was approved by the Ethics Committee of the National Center for Global Health and Medicine (NCGM-H20–580; approved on 7th February 2008). All participants provided their written informed consent before enrollment as indicated in the protocol.

The protocol for this study and supporting CONSORT checklist are available as supporting information; see File S1 for English translation of the protocol and File S2 for the Japanese original protocol and File S3 for CONSORT checklist.

Study design
Consecutive patients with HIV-1-related mycobacterial infections who received rifabutin-containing therapy at the National Center for Global Health and Medicine, Tokyo, Japan, between February 2008 and March 2009, were eligible for the study. After their written informed consent was provided, clinical history, physical examinations and laboratory tests (e.g., blood chemistry and complete blood cell count) were carried out within one week prior to the pharmacokinetic study. Patients were excluded if they were over 20 years of age or if they had abnormal liver function tests [aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin (>3 times the upper limit of normal: ULN)], or severe renal dysfunction (creatinine clearance <30 ml/min), and in the case of female patients if they were pregnant or breastfeeding. Rifabutin was administered while fasting at 300 mg/day and the dose was adjusted when used with cART as recommended by the treatment guideline at the time of the study [13]. Medications administered concomitantly or within 2 weeks before the first study day were recorded. To evaluate the impact of rifabutin plasma concentration on treatment efficacy and adverse events, participants were followed up for at least 2 years after stopping rifabutin. Any side effect noted during rifabutin use or within four weeks after stopping rifabutin, its association with rifabutin was assessed.

Pharmacokinetic assays
Pharmacokinetic sampling commenced after 5 days of rifabutin-containing anti-mycobacterial therapy without (Group I) or with (Group II) cART. Sequential enrollment of a patient into both groups was accepted. Blood samples were collected just before rifabutin administration and then 0.5, 1, 2, 4, 6, 8 and 24 hours afterward. Patients of Group II treated with 150 mg of rifabutin every other day underwent additional sampling at 48 hours. The plasma concentrations of rifabutin and its major metabolite, 25–O-desacyethyl rifabutin [20–23] were determined simultaneously by validated high-pressure liquid chromatography (HPLC). Blood samples were taken in heparin-containing tubes, placed on ice and centrifuged at 3000 g for 10 min. Then, the obtained plasma was deproteinized by using three times volume of methanol and centrifuged 15,000 g for 5 min, and the supernatant was used for assay. The HPLC standard for rifabutin and 25-O-desacyethyl rifabutin were kindly provided by Pfizer Co. (Pfizer, Inc., NY). The HPLC system consisted of Agilent 1100 series (Agilent Technologies, Santa Clara, CA). Isocratic elution was performed using the Inertsil ODS-3 column (5 μm, 4.6 mm I.D. × 150 mm; GL Sciences Inc, Tokyo, Japan) with a guard column (5 μm, 4.6 mm I.D. × 10 mm; GL Sciences Inc). The UV detection wavelength was 280 nm. The mobile phase consisted of 9 mM

Table 1. Characteristics of study subjects.

|                         | All (n = 16) | Group I (without cART, n = 9) | Group II (with cART, n = 7) | p value * |
|-------------------------|-------------|------------------------------|-----------------------------|-----------|
| Male sex, n             | 16          | 9                            | 7                           |           |
| Age, median years (range)| 36 (23–60) | 36 (23–55)                   | 35 (23–60)                  | 0.53      |
| Body weight, median kg (range) | 57.3 (44–66) | 58.0 (46–64)               | 56.5 (44–66)               | 0.98      |
| Mycobacterium, multiple choice, n |           |                              |                             |           |
| M. tuberculosis         | 13          | 7                            | 6                           | 1.00      |
| M. avium               | 4           | 3                            | 1                           | 0.94      |
| M. kansasii            | 1           | 0                            | 1                           | 0.85      |
| CD4 count, median cells/mm³ (range) | 63 (2–164) | 63 (2–164)                   | 63 (19–135)                | 0.84      |
| Plasma viral load, median log copies/ml (range) | 4.97 (3.43–6.62) | 4.98 (4.18–6.62) | 4.95 (3.43–5.18) | 0.10      |
| AST, median IU/L (range) | 29 (16–70) | 25 (16–59)                   | 30 (17–51)                 | 0.65      |
| ALT, median IU/L (range) | 27 (13–70) | 26 (23–70)                   | 29 (19–70)                 | 0.31      |
| Time on rifabutin, median days (range) | 15 (5–63) | 7 (5–20)                     | 29 (10–63)                 | 0.017     |
| Time on cART, median days (range) | 14 (10–29) | –                            | 14 (10–29)                 | –         |
| Concomitant medications, n |           |                              |                             |           |
| lopinavir-ritonavir     | 7           | –                            | 7                           |           |
| clarithromycin          | 3           | 2                            | 1                           | 1.00      |
| fluconazole            | 1           | 0                            | 1                           | 0.85      |

*By Fisher’s exact test for categorical data and Mann Whitney’s U test for continuous variables.
cART, combination antiretroviral therapy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit.
doi:10.1371/journal.pone.0070611.t001
phosphate buffer (pH 6.8)-acetonitrile (30:70, v/v). The flow-rate was set at 1.0 ml/min and all separations were performed at 30°C in column oven.

**Statistical and pharmacokinetic analyses**

The area under the curve (AUC) was calculated using non-compartmental techniques (WinNonlin, ver. 5, Pharsight Corp., Mountain View, CA) based on the obtained values (AUC 0–24 h for all, AUC 0–48 h for Group II). The maximum plasma concentration (Cmax) and time of Cmax (Tmax) were determined directly from the data.

Statistical analyses were performed using SPSS software package for Windows, version 17.0J (SPSS Japan Inc, Tokyo). Differences between groups were determined by using the Fisher’s exact test for categorical data and the Mann Whitney’s test for continuous variables. For all statistical analyses, differences were considered significant if the p value was less than 0.05.

**Results**

**Patient characteristics**

A total of 15 patients were enrolled in the study and 5 of 15 participated in both Group I and II. In total, twenty sampling was done for rifabutin pharmacokinetic analysis; 11 in Group I and 9 in Group II. Data from two sampling in Group I and 2 in Group II were excluded from the analysis because samples at 24-hour were unavailable or sampling was conducted earlier than 5 days of rifabutin use. As a result, data from 9 sampling in Group I and 7 sampling in Group II were used for analysis. The baseline characteristics of the 16 sampling cases are summarized in Table 1. All 7 patients of Group II were being treated with lopinavir/ritonavir as their cART, and thus rifabutin was administered at 150 mg every other day based on the guidelines at the time of the study [13]. Two cases of Group I and 1 of Group II were being treated with clarithromycin (CAM) [20] for systemic mycobacterial infection caused by *M. avium* or *M. intracellulare* (*M. avium* Complex: MAC). Five patients of Group I, in whom ART had been delayed several weeks after anti-mycobacterial therapy to prevent the immune reconstitution inflammatory syndrome (IRIS), were later enrolled in the study as patients of Group II (Figure 1). Accordingly, the median time of rifabutin use was longer in Group II than in Group I. There was no significant difference between the groups with regard to gender, age, body weight, CD4 counts, HIV-RNA load, type of mycobacteria and concomitant use of clarithromycin or fluconazole. All were Japanese and the median body weight was 57.3 kg. All patients completed their anti-

---

**Figure 1. Flow chart of participants through the study.** PK, pharmacokinetic; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0070611.g001
Table 2. Pharmacokinetic parameters for rifabutin and 25-O-desacetyl rifabutin.

|                          | Group I (without combination antiretroviral therapy, n = 9) | Group II (with combination antiretroviral therapy, n = 7) | P value* |
|--------------------------|------------------------------------------------------------|-----------------------------------------------------------|----------|
|                          | Median (range)     | Mean (90% CI)     | Median (range)     | Mean (90% CI)     |           |
| Rifabutin                |                 |                  |                    |                  |          |
| Cmax (μg/mL)             | 0.46 (0.15–0.86) | 0.44 (0.39–0.49) | 0.28 (0.10–0.44)   | 0.29 (0.25–0.33) | 0.10     |
| AUC0–24 (μg h/mL)        | 2.79 (1.32–15.7) | 4.86 (3.83–5.90) | 3.00 (1.13–5.43)   | 3.38 (2.92–3.84) | 0.38     |
| AUC0–48 (μg h/mL)        | 5.59 (2.63–31.3) | 9.71 (7.62–511.8) | 4.21 (1.76–6.90)   | 4.58 (3.38–5.78) | 0.32     |
| Tmax (h)                 | 2.0 (2.0–4.0)    | 2.9 (2.6–3.1)    | 6.0 (2.0–12.0)     | 4.8 (4.1–5.1)    | 0.03     |
| 25-O-desacetyl rifabutin |                 |                  |                    |                  |          |
| Cmax (μg/mL)             | 0.00 (0.00–0.30) | 0.05 (0.03–0.08) | 0.13 (0.05–0.23)   | 0.14 (0.12–0.16) | 0.05     |
| AUC0–24 (μg h/mL)        | 0.00 (0.00–3.69) | 0.82 (0.45–1.20) | 1.52 (0.44–3.64)   | 2.07 (1.62–2.52) | 0.12     |
| AUC0–48 (μg h/mL)        | 0.00 (0.00–7.38) | 1.64 (0.89–2.39) | 5.93 (0.44–7.21)   | 4.32 (3.27–5.38) | 0.15     |
| Tmax (h)                 | 6.0 (2.0–8.0)    | 5.3 (4.6–6.0)    | 6.0 (2.0–12.0)     | 5.7 (4.6–6.9)    | 0.87     |
| Rifabutin plus 25-O-desacetyl rifabutin |                 |                  |                    |                  |          |
| Cmax (μg/mL)             | 0.47 (0.15–0.99) | 0.49 (0.40–0.52) | 0.42 (0.16–0.56)   | 0.39 (0.34–0.44) | 0.54     |
| AUC0–24 (μg h/mL)        | 3.36 (1.32–19.3) | 5.49 (4.18–6.76) | 6.23 (1.57–7.92)   | 5.27 (4.48–6.07) | 0.93     |
| AUC0–48 (μg h/mL)        | 6.72 (2.63–38.7) | 10.9 (8.35–13.5) | 6.80 (2.20–14.1)   | 7.95 (6.40–9.49) | 0.46     |

*By the Mann Whitney’s U test.

In Group I, AUC0–24 is assumed the same as AUC0–48 and AUC0–48 is calculated as double of AUC0–48 for comparison with Group II.

Cmax, maximum plasma concentration; AUC, area under the curve; Tmax, time of Cmax; CI, confidence interval.

doi:10.1371/journal.pone.0070611.t002

Pharmacokinetic parameters of rifabutin and its 25-O-desacetyl metabolite

The pharmacokinetic parameters of rifabutin and 25-O-desacetyl rifabutin are summarized in Table 2 and their mean plasma concentration-time data of 48 hours are illustrated in Figure 2A and 2B. For calculation of AUC0–48, the data from 24 to 48 hours in Group I was assumed to be the same as that for 0–24 hours because rifabutin was administered once a day at the same dosage. As shown in Table 2, the mean values of Cmax and AUC0–24 of rifabutin were 36% and 26% lower in Group II than in Group I, while the mean values of Cmax and AUC0–24 of 25-O-desacetyl rifabutin were 186% and 152% higher in Group II than in Group I. However, the differences in the above values between the two groups were not statistically different. The low rifabutin concentration and high metabolite concentration in Group II may reflect the induction of rifabutin metabolism due to the longer duration of rifabutin use. Since 25-O-desacetyl rifabutin is microbiologically active against mycobacterium, total rifabutin activity might include rifabutin plus this metabolite. Figure 2C illustrates the mean plasma concentration of rifabutin plus the metabolite over time. Patients of Groups I and II had similar plasma concentrations of rifabutin plus the metabolite within the first 24 hours. However, the level of rifabutin plus the metabolite during the subsequent 24–48 hours was considerably lower in Group II than in Group I (dotted line in Figure 2C: Group I during 0–24 hours), whereas the AUC0–48 was not statistically different between the groups. Notably, 6 (67%) cases of Group I and 5 (71%) of Group II failed to achieve the AUC0–24 value suggested as risk for emergence of rifamycin-resistant M. tuberculosis [14] (4.5 μg/h/mL). Neither Cmax nor AUC0–24 of rifabutin and 25-O-desacetyl rifabutin were associated with age, body weight, body mass index, or CD4 count.

Rifabutin-associated side effects

Of the 15 participants, three patients developed side effects possibly related to rifabutin during the observational period; two of Group I developed skin rash and the other of Group II developed grade 2 rise in liver enzymes (ALT or AST 2.6–5.0 times of ULN). The skin rash appeared on day 11 of rifabutin-containing regimen in one patient and on day 28 in the other, and was resolved in both patients within several days after withdrawal of rifabutin. The rise in liver enzymes was detected after two months of rifabutin-containing regimen in combination with cART, and improved soon after discontinuation of rifabutin. Notably, the median CD4 counts in the three patients with rifabutin toxicity were significantly lower than in patients without rifabutin toxicity (12 vs 76, cells/mm3, p = 0.028). However, rifabutin toxicity did not correlate with rifabutin AUC0–24, Cmax, or the concurrent use of cART (rifabutin AUC0–24: p = 0.37, rifabutin Cmax: p = 0.86, cART use: p = 0.21).

Discussion

In the present study, a low dose of rifabutin (150 mg every other day), in combination with lopinavir/ritonavir-containing cART, yielded comparable AUC0–24 of rifabutin and 25-O-desacetyl rifabutin to the commonly used dose of rifabutin of 300 mg/day. The advantage of the low-dose rifabutin included lower exposure to rifabutin and metabolite during the subsequent 24 to 48 hours in Japanese patients with HIV-mycobacteria co-infection. Since many participants started their cART after at least 1 month of...
Pharmacokinetics of Rifabutin in HIV Patients

Figure 2. Mean plasma concentrations-versus-time plots of rifabutin (A), 25-O-desacetyl rifabutin (B), and rifabutin plus 25-O-desacetyl rifabutin (C). Nine patients of Group I received 300 mg of rifabutin and 7 patients of Group II received 150 mg of rifabutin every other day with lopinavir/ritonavir-containing antiretroviral therapy. Solid circles: Group I, open circles: Group II. Data are mean ± 1 standard errors. Dotted line in Figure C represents data of Group I during 0–24 hour for reference. RBT, rifabutin; PI/r, ritonavir-boosted protease inhibitor.

doi:10.1371/journal.pone.0070611.g002

anti-mycobacterial therapy in order to avoid deterioration by immune-reconstitution syndrome, the metabolism of rifabutin was induced upon the commencement of cART. This led to lower rifabutin concentration and higher 25-O-desacetyl rifabutin concentration in Group II but provided similar concentrations of rifabutin plus its active metabolite. However, on the day without medication, plasma concentrations of rifabutin and its active metabolite were lower in Group II, which were less than the susceptibility breakpoint level for M. tuberculosis proposed by others [20]. This suggests increased risk of emergence of rifamycin-resistant M. tuberculosis during the day without medication under low-dose rifabutin therapy, and that the currently recommended dosage 150 mg daily with PI/r is reasonable to this population as well. In this regard, Zhang et al. [11] reported that treatment with 150 mg/day rifabutin with atazanavir-ritonavir resulted in high risk of severe neutropenia. Furthermore, their post-hoc simulation showed that rifabutin 150 mg thrice weekly with atazanavir-ritonavir provided a comparable exposure to rifabutin compared with rifabutin 300 mg daily. Considering the risk of rifamycin-resistance and rifabutin toxicity, monitoring of rifabutin plasma concentration should be considered until the optimal rifabutin dosing during PI/r-based cART is fully established.

Although none of the patients showed treatment failure or relapse in this study, the rifabutin AUC0-24 observed in the study was in general close to the low end of the value reported in previous studies [7,14] and many participants [6 (67%) of Group I and 5 (71%) of Group II] failed to achieve AUC0-24 4.5 μg/mL, the cutoff value suggested as risk for emergence of rifamycin-resistant M. tuberculosis [14]. One of the reasons for this discordant result might be the limitation of our study of small sample size involving several MAC and M. kansasii infections. Since acquisition of rifamycin-resistance M. tuberculosis was not frequent enough in this study group, it was difficult to evaluate the association with rifabutin pharmacokinetics and emergence of rifamycin-resistance. Other reasons may be the biological characteristics of rifabutin. Rifabutin has long postantibiotic effect against M. tuberculosis and MAC [20], shows extensive distribution in various tissues [21,22], and readily penetrates cell membranes of leucocytes [21,22]. These characteristics and their variations among patients can considerably influence the outcome of rifabutin-containing anti-mycobacterial therapy and therefore might be one of the explanations of favorable efficacy despite lower plasma concentrations of rifabutin in our study. Another limitation of this study is that plasma concentration of isoniazid was not measured, although low isoniazid plasma concentration is known to be independently related to treatment failure of HIV/TB co-infection [24]. Additionally, although there was no difference in rifabutin concentration among the patients with or without use of clarithromycin or fluconazole, those drugs can increase the rifabutin AUC and possibly affect the results. Since our study was enrolling patients with heterogeneous backgrounds in the real clinical setting, such as timing of sampling or different combination of anti-mycobacterial drugs, it was difficult to completely eliminate those impacts from the analysis. These conditions should be taken into account in the assessment of treatment outcome and associated factors in this study.

Among 15 study participants, 3 patients developed side effects related to rifabutin therapy, including skin rash and rise in liver enzymes. Notably, their CD4 counts were lower than those who did not show rifabutin toxicity, although rifabutin plasma concentrations and the concurrent use of cART were similar in the two groups. This is the first report implicating low CD4 count as a risk factor for rifabutin-related side effects. However, like other side effects of rifabutin, such as uveitis and leukocytopenia, which have been reported to be related to high-dose rifabutin or high rifabutin plasma concentrations [9–12], careful assessment involving larger population samples are needed to evaluate the association between high plasma concentrations of rifabutin and the related skin rash and hepatotoxicity.

In conclusion, in Japanese patients with HIV-mycobacteria co-infection, the plasma concentrations of rifabutin and active metabolite within the first 24 hours of treatment with low-dose rifabutin (150 mg every other day) combined with lopinavir-ritonavir, were similar to those encountered with 300 mg/day rifabutin alone. However, these concentrations decreased on the day without medication. Our findings could help determine the optimal dose of rifabutin during cART. Further studies are needed to establish the optimal dose of rifabutin during cART. Monitoring of rifabutin plasma concentration should be considered in patients with HIV-mycobacteria co-infection.
Supporting Information

Protocol S1 Summary in English. English translation of the protocol Summary.

Protocol S1 Protocol and IC form in Japanese. The full version of the study protocol and the informed consent form in Japanese.

CONSORT Checklist S2.

References

1. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 6: 603–662.
2. Pfizer, Inc. Mycobutin (rifabutin) prescribing information. Pfizer, Inc., New York, NY. Available: http://www.pfizer.com/files/products/uspi_mycobutin.pdf. Accessed 2012 August 21.
3. Centers for Disease Control and Prevention. (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 58: 1–207.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 2012 August 21.
5. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, et al. (2004) Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 44: 305–313.
6. Ford SL, Chen YC, Lou Y, Borland J, Min SS, et al. (2008) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 52: 534–538.
7. Boulander C, Hollender E, Farrell K, Stambough JJ, Maassen D, et al. (2009) Pharmacokinetic evaluation of rifabutin and lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 49: 1305–1311.
8. Zhang X, Fettner S, Zwaninger E, Rowell L, Salge M, et al. (2011) Pharmacokinetic interaction study of rifabutin-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother 55: 680–687.
9. Centers for Disease Control and Prevention. (1994) Uveitis associated with rifabutin therapy. MMWR 43: 658.
10. Shahriar SD, Singer J, Zarowitz DP, Deschenes J, Phillips P, et al. (1998) Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 177: 252–255.
11. Zhang J, Zhi L, Stoner M, Combins J, Xu X, et al. (2011) Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother 66: 2075–2082.
12. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, et al. (2010) Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 54: 4440–4445.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3: 1–139. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2012 August 21.
14. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, et al. (2005) Association between acquired rifampicin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40: 1481–1491.
15. Jenny-Avital ER, Joseph K (2009) Rifaximin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifampin and boosted protease inhibitor therapy. Clin Infect Dis 48: 1471–1474.
16. Li J, Mansiif SS, Driver CR, Sackoff J (2003) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin–or rifabutin-based regimens in New York City. 1997–2000. Clin Infect Dis 41: 83–91.
17. Khachi H, O’Connell R, Laidenheim D, Orkin C, et al. (2009) Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial coinfection. J Antimicrob Chemother 64: 871–873.
18. Gomez A, Ingelman-Sundberg M (2009) Pharmacoenzyme: its role in interindividual differences in drug response. Clin Pharmacol Ther 85: 426–430.
19. Lee IS, Kim D (2011) Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res 34: 1799–1816.
20. Kunin CM (1996) Antimicrobial activity of rifabutin. Clin Infect Dis 22: S15–21.
21. Skinner MH, Hsieh M, Torsett J, Pauloin D, Bhartia G, et al. (1989) Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 33: 1237–1241.
22. Blaschke TF, Skinner MH (1996) The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22: S15–21.
23. Strohl Benedetti M, Ethlymoppoulos C, Sassella D, Mero E, Repetto M (1990) Autoinduction of rifabutin metabolism in man. Xenobiotica 20: 1113–1119.
24. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, et al. (2005) Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 167: 1341–1347.

Acknowledgments

We thank all the staff of the AIDS Clinical Center for the care of the patients.

Author Contributions

Conceived and designed the experiments: JT. Performed the experiments: JT KS. Analyzed the data: JT. Contributed reagents/materials/analysis tools: JT KS. Wrote the paper: JT. Technical advice: YK. Patients’ recruitment: K. Tsuchida Technical advice: K. Teruya HG SO.